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Fifty years ago, Ashbaugh and colleagues described 12 patients with tachypnea, refractory hypoxemia, and diffuse opacities on chest radiographs af-ter infection or trauma.1 Prominent hyaline membranes were seen lining the al-
veolar spaces of the lungs in 6 of the 7 patients who died, findings previously thought 
to be specific for the respiratory distress syndrome of the newborn. Thus, the term 
adult (later changed to acute) respiratory distress syndrome (ARDS) was proposed.
Since ARDS was last reviewed in the Journal, 17 years ago,2 substantial progress 
has been made in the care of affected patients and those at risk for the disorder, 
with reductions in both incidence and mortality. However, ARDS remains a rela-
tively common and lethal or disabling syndrome. In a recent international study 
involving 29,144 patients,3 10% of all patients admitted to the intensive care unit 
(ICU) and 23% of mechanically ventilated patients had ARDS. Mortality in the 
subgroup of patients with severe ARDS was 46%.3 Patients who survive this disor-
der are at high risk for cognitive decline, depression, post-traumatic stress disorder, 
and persistent skeletal-muscle weakness.4,5
Defini tion a nd Pathol o gic a l Fe at ur es
Four major definitions of ARDS have evolved over the years, and all have retained 
the central features of the initial description by Ashbaugh and colleagues. Because 
lung permeability, edema, and inflammation are not routinely measured in clinical 
care and no validated diagnostic biomarkers are yet available, these definitions rely 
on clinical features and chest imaging as surrogates. The Berlin definition, pro-
posed in 2012,6 breaks with tradition by establishing three risk strata that are 
based on the degree of hypoxemia as assessed at a minimum positive end-expira-
tory pressure (PEEP) (Table 1). The definition makes the radiographic criteria more 
explicit and allows the use of computed tomography (CT) for the detection of 
qualifying opacities, which are often heterogeneous (Fig. 1). In addition, the defi-
nition acknowledges that if ARDS develops, it usually does so within 7 days after 
clinical recognition of a known risk factor, most commonly pneumonia or sepsis 
(Table 2). ARDS with a more indolent onset or in the absence of an identifiable 
risk factor should prompt consideration of so-called ARDS mimics, a large number 
of diseases or syndromes that may require specific treatments (Table 3).8 Prior 
definitions excluded volume overload or heart failure, but recent evidence suggests 
that these problems may coexist in up to a third of patients with ARDS.
The histologic correlate of ARDS is widely considered to be “diffuse alveolar 
damage,” a term coined by Katzenstein and colleagues9 almost a decade after the 
report by Ashbaugh et al.1 Katzenstein and colleagues described the rapid develop-
ment of capillary congestion, atelectasis, intraalveolar hemorrhage, and alveolar 
edema, followed days later by hyaline-membrane formation, epithelial-cell hyperpla-
sia, and interstitial edema. Animal models of ARDS have been developed in an effort 
to recapitulate these histologic findings. However, the Berlin definition (as well as 
the 1994 American–European Consensus Conference definition10) has poor specific-
ity for diffuse alveolar damage. At postmortem examination, 40 to 58% of patients 
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with a clinical diagnosis of moderate-to-severe 
ARDS have diffuse alveolar damage. Pulmonary 
edema and pneumonia without hyaline mem-
branes are the next most common findings, al-
though 14% of patients have no pulmonary le-
sions whatsoever, probably because of atelectasis 
masquerading as ARDS.11,12 Similar or lower 
proportions of patients have diffuse alveolar 
damage on lung biopsy. Furthermore, the overall 
proportion of patients with diffuse alveolar 
damage at postmortem examination has fallen 
from 49% to 41% in the past decade, as me-
chanical ventilation with tidal volumes on the 
order of 6 ml per kilogram of ideal body weight 
has become common.12 Thus, diffuse alveolar 
damage is best thought of as a common histo-
logic finding in patients with ARDS that may, in 
part, reflect ventilator-induced lung injury.
Epidemiologic Featur es
Population-based estimates of ARDS range from 
10 to 86 cases per 100,000, with the highest rates 
reported in Australia and the United States.13 
ARDS is likely to be underreported in low-income 
countries, where resources to obtain chest radio-
graphs and measure arterial blood gases are 
limited. In Kigali, Rwanda, for example, Riviello 
and colleagues14 found no cases of ARDS when 
they applied the Berlin definition, but with the 
substitution of lung ultrasonography for radiog-
raphy or CT and percutaneous oxygen satura-
tion for blood gas measurements, they identified 
4 cases per 1000 hospital admissions, with a 
50% mortality rate.
Even in high-income countries, ARDS remains 
underrecognized. A recent observational study of 
459 ICUs in 50 countries showed clinical recog-
nition rates ranging from 51.3% for mild ARDS 
to 78.5% for severe ARDS.3 Underuse of currently 
recommended lung-protective practices was seen 
across the severity spectrum, suggesting both 
underrecognition and undertreatment. One ex-
planation for the underdiagnosis of ARDS may be 
disagreement about the nature of the radiograph-
ic opacities that support the diagnosis. Diffuse, 
confluent opacities with a narrow cardiothoracic 
silhouette (suggesting noncardiogenic edema) are 
the classic findings, but imaging often shows 
asymmetric, dependent, and occasionally lobar 
opacities (Fig. 1). Patients with multifocal opac-
ities have been enrolled in ARDS clinical trials 
for decades and benefit from lung-protective ven-
tilation.15 Computerized detection algorithms 
reliably identify ARDS from the electronic med-
ical record in real time and offer a solution to 
the problem of underrecognition at some ter-
tiary care centers, but such algorithms have not 
been widely implemented or validated.16
Genetic Features and Biomarkers
ARDS does not develop in the majority of pa-
tients with clinical risk factors for the disease 
Criteria Rationale
Onset within 7 days after a known clinical insult or 
new or worsening respiratory symptoms
Observational data suggest that ARDS will develop within 72 hr in the majority of patients 
at risk for the syndrome and within 1 wk in nearly all patients at risk
Bilateral opacities that are “consistent with pul­
monary edema” on chest radiographs or 
chest CT
There is poor interobserver reliability in interpreting the chest radiograph for the presence 
of edema. To address this issue, the Berlin definition offers more explicit criteria (e.g., 
opacities should not be fully explained by effusions, lobar or lung atelectasis, or nod­
ules or masses), with illustrative radiographs provided
Categorization of ARDS severity A patient­level meta­analysis validated three thresholds for hypoxemia, all consisting of  
a Pao2:Fio2 ratio ≤300 mm Hg
Mild Pao2:Fio2, 201 to 300 mm Hg; mortality, 27% (95% CI, 24–30)
Moderate Pao2:Fio2, 101 to 200 mm Hg; mortality, 32% (95% CI, 29–34)
Severe Pao2:Fio2, ≤100 mm Hg; mortality, 45% (95% CI, 42–48)
Minimum PEEP setting or CPAP, 5 cm of water; 
Pao2:Fio2 assessed on invasive mechanical 
ventilation (CPAP criterion used for the diag­
nosis of mild ARDS)
Estimates of Fio2 are not accurate with oxygen­delivery systems other than invasive or non­
invasive ventilation (with a tight­fitting mask), with the exception of nasal high­flow oxy­
gen delivery systems (at flow rates ≥45 liters per minute); requiring higher PEEP settings 
does not increase predictive validity of the Berlin severity strata and adds complexity
*  The definition and the quotation about opacities are from Ferguson et al.6 CI denotes confidence interval, CPAP continuous positive airway 
pressure, Pao2:Fio2 ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen, and PEEP positive end­expiratory pressure.
Table 1. Berlin Definition of the Acute Respiratory Distress Syndrome (ARDS).*
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(e.g., pneumonia, sepsis, or trauma), suggesting 
that other factors, including genetic susceptibil-
ity, play a key role in the pathogenesis of this 
disorder. However, differences in virulence fac-
tors (e.g., H1N1 influenza), coexisting condi-
tions (e.g., pneumococcal pneumonia after sple-
nectomy), and environmental exposures (alcohol 
use or active smoking and injurious mechanical-
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ventilation practices)17 complicate the interpreta-
tion of genetic findings. More than 40 candidate 
genes associated with the development or out-
come of ARDS have been identified, including 
the genes encoding angiotensin-converting en-
zyme (ACE), interleukin 10 (IL-10), tumor necro-
sis factor (TNF), and vascular endothelial growth 
factor (VEGF), as well as SOD3, MYLK, NFE2L2, 
NAMPT, and SFTPB.18 In the one genomewide 
association study that has been reported for 
trauma-associated ARDS, no polymorphism had 
genomewide significance.19 As with other dis-
eases, the biologic importance of the genetic 
association is strengthened by additional studies 
that implicate the same pathway. For example, 
ACE has been associated with overall susceptibil-
ity to ARDS,20 and the ACE2 protein is the recep-
tor for the severe acute respiratory syndrome 
coronavirus (SARS-CoV).21,22 Experimentally in-
duced lung injury from SARS-CoV can be atten-
uated by blocking the renin–angiotensin path-
way,22,23 suggesting both a molecular explanation 
for the severe ARDS that follows SARS-CoV in-
fection and a possible treatment.
Sequencing of genomic coding regions (exome 
sequencing) identified polymorphisms in the 
genes encoding arylsulfatase D (ARSD) and X Kell 
blood-group precursor–related family, member 3 
(XKR3) and showed differences in expression 
between patients with ARDS and healthy con-
trols, but these findings require replication.24 
Exome sequencing has also shown that more 
than one genetic variant may explain a clinical 
phenotype. Thus, some persons may have mul-
tiple variants that modify the risk of ARDS and 
the outcome of ARDS, which may go undetected 
or at least lead to imprecise risk estimates.25 In 
addition, lung tissue for discovery research is 
generally not available from patients with ARDS, 
and even within the lung compartment, there 
are a number of different cell types that may not 
be cleanly separated. Thus, the overall success of 
linking candidate genes with ARDS susceptibil-
ity and outcomes, as well as with downstream 
biologic events (e.g., transcriptional and epigen-
etic events or protein expression), remains limit-
ed. Microengineered “lungs on a chip” and iso-
lated perfused human lungs are two preclinical 
platforms that have the potential to bridge these 
gaps but have yet to be proved useful in identify-
ing new treatments.26,27
Increased levels of plasma biomarkers, includ-
ing markers of systemic inflammation (interleu-
kin-6 and interleukin-8), epithelial injury (recep-
tor for advanced glycation end products and 
surfactant protein D), and endothelial injury 
(angiopoietin 2), as well as markers of dysregu-
Direct lung-injury risk factors
Pneumonia (bacterial, viral, fungal, or opportunistic)*
Aspiration of gastric contents*
Pulmonary contusion
Inhalation injury
Near drowning
Indirect lung-injury risk factors
Sepsis (nonpulmonary source)*
Nonthoracic trauma or hemorrhagic shock
Pancreatitis
Major burn injury
Drug overdose
Transfusion of blood products
Cardiopulmonary bypass
Reperfusion edema after lung transplantation or embo­
lectomy
*  Pneumonia, aspiration of gastric contents, and sepsis 
 together account for more than 85% of cases of ARDS  
in recent clinical trials.
Table 2. Risk Factors for ARDS.Figure 1 (facing page). Radiographic Heterogeneity in 
Patients with the Acute Respiratory Distress Syndrome 
(ARDS).
Panels A through D are radiographs included with the 
publication of the Berlin definition6 that meet the diag­
nostic criteria for ARDS. The radiographs and an explicit 
definition of qualifying opacities were published with the 
goal of reducing poor interobserver reliability. Qualify­
ing opacities must be bilateral and “consistent with pul­
monary edema”; furthermore, the opacities cannot be 
“fully explained by effusions, lobar/lung collapse, or 
nodules/masses on chest radiograph.”6 The Berlin defi­
nition also recognizes the use of CT for the detection 
of qualifying opacities so that a CT scan can be substi­
tuted for the chest radiograph.6 Panel E is a CT image 
showing the heterogeneous nature of the opacities often 
seen in patients with ARDS, as exemplified in Panels C 
and D, and Panel F is an 18F­fluorodeoxyglucose (FDG) 
positron­emission tomographic image corresponding 
to the CT image in Panel E.7 Intense FDG uptake, largely 
from metabolically active inflammatory cells, is observed 
in normally aerated regions that receive a relatively larger 
fraction of the delivered tidal volume (rectangle 1 in Pan­
els E and F), probably reflecting volutrauma. Activity is 
lower in the dorsal, nonaerated regions of both lungs 
(rectangle 2 in Panels E and F), in part reflecting atelecta­
sis. All images have been reprinted from Ferguson et al.6 
and Bellani et al.7 with the permission of the publishers.
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lated coagulation (low protein C and high plas-
minogen activator inhibitor 1 levels), have been 
associated with adverse outcomes of ARDS. These 
biomarkers provide insights into the pathogenesis 
of ARDS and may identify treatment-responsive 
subtypes (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org).
Patho genesis
Figures 2 and 3 provide an overview of the 
pathogenesis of ARDS; a detailed review can be 
found in the Supplementary Appendix. The lung’s 
initial response to injury, referred to as the exu-
dative phase of ARDS, is characterized by innate 
immune cell–mediated damage of the alveolar 
endothelial and epithelial barriers and accumu-
lation of protein-rich edema fluid within the 
interstitium and alveolus (Fig. 2). Resident alveo-
lar macrophages secrete proinflammatory cyto-
kines, leading to neutrophil and monocyte or 
macrophage recruitment, as well as activation 
of alveolar epithelial cells and effector T cells, to 
promote and sustain inflammation and tissue 
injury.29 Endothelial activation and microvascu-
lar injury also contribute to the barrier disrup-
tion in ARDS and are worsened by mechanical 
stretch. The repair processes initiated during the 
second, or proliferative, phase of ARDS are es-
sential for host survival (Fig. 3A). Once epithe-
lial integrity has been reestablished, reabsorp-
tion of alveolar edema and the provisional matrix 
restores alveolar architecture and function. The 
final, or fibrotic, phase of ARDS (Fig. 3B) does 
not occur in all patients but has been linked to 
prolonged mechanical ventilation and increased 
mortality.
Tr e atmen t a nd Pr e v en tion
Supportive Therapy
The first priority in the care of patients with 
ARDS is identification and treatment of the un-
derlying cause (or causes). For example, in pa-
tients with sepsis-associated ARDS, good out-
comes require early resuscitation, appropriate 
antibiotic agents, and source control.30
Supportive therapy for ARDS is focused on 
limiting further lung injury through a combi-
nation of lung-protective ventilation to prevent 
ventilator-associated lung injury (reviewed in the 
Journal in 2013 by Slutsky and Ranieri31) and 
conservative fluid therapy to prevent lung edema 
formation and promote lung edema resorption. 
The optimal approach to lung-protective ventila-
tion is unknown. Current evidence suggests that 
there may be no safe level of tidal volume or 
airway pressure in patients with acute lung in-
Congestive heart failure
Interstitial lung disease (e.g., acute interstitial pneumonia, nonspecific interstitial 
pneumonitis, cryptogenic organizing pneumonia, acute eosinophilic pneu­
monia, hypersensitivity pneumonia, and pulmonary alveolar proteinosis)
Connective­tissue diseases such as polymyositis (antisynthetase syndrome)
Diffuse alveolar hemorrhage from vasculitis or Goodpasture’s syndrome
Drug­induced lung diseases (e.g., bleomycin or amiodarone), including vascu­
lar leak syndrome from immunotherapy
Cancer (T­cell or B­cell lymphomas or metastatic carcinoma)
Endobronchial tuberculosis
*  These conditions, referred to as “ARDS mimics” or “secondary causes” in the 
literature, may require additional diagnostic tests and treatments distinct 
from those for ARDS.8
Table 3. Conditions That May Mimic ARDS.* Figure 2 (facing page). The Healthy Lung  
and the Exudative Phase of ARDS.
The healthy lung is shown on the left, and the exudative 
phase of ARDS is shown on the right. Injury is initiated 
by either direct or indirect insults to the delicate alveo­
lar structure of the distal lung and associated micro­
vasculature. In the exudative phase, resident alveolar 
macrophages are activated, leading to the release of 
potent proinflammatory mediators and chemokines 
that promote the accumulation of neutrophils and mono­
cytes. Activated neutrophils further contribute to injury 
by releasing toxic mediators. The resultant injury leads 
to loss of barrier function, as well as interstitial and intra­
alveolar flooding. Tumor necrosis factor (TNF)–medi­
ated expression of tissue factor promotes platelet ag­
gregation and microthrombus formation, as well as 
intraalveolar coagulation and hyaline­membrane forma­
tion. AECI denotes type I alveolar epithelial cell, AECII 
type II alveolar epithelial cell, Ang­2 angiopoietin­2, APC 
activated protein C, CC­16 club cell (formerly Clara cell) 
secretory protein 16, CCL chemokine (CC motif) ligand, 
DAMP damage­associated molecular pattern, ENaC 
epithelial sodium channel, GAG glycosaminoglycan, 
HMGB1 high­mobility group box 1 protein, KL­6 Krebs 
von den Lungen 6, LPS lipopolysaccharide, LTB4 leuko­
triene B4, MMP matrix metalloproteinase, MPO myelo­
peroxidase, mtDNA mitochondrial DNA, Na+/K+ ATPase 
sodium–potassium ATPase pump, NF­κB nuclear fac­
tor kappa light­chain enhancer of activated B cells, NET 
neutrophil extracellular trap, PAMP pathogen­associated 
molecular pattern, PRR pattern recognition receptor, 
ROS reactive oxygen species, sICAM soluble intercellu­
lar adhesion molecule, SP surfactant protein, sRAGE 
soluble receptor for advanced glycation end products, 
VEGF vascular endothelial growth factor, and vWF von 
Willebrand factor.
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jury. Because the volume of aerated lung is re-
duced in patients with ARDS, even normal tidal 
volumes delivered with airway pressures that are 
considered safe for the uninjured lung may 
cause regional overdistention (so-called volu-
trauma), further activating or injuring the epi-
thelium and amplifying inflammation. Repeti-
tive opening and closing of lung units 
(atelectrauma) amplifies regional lung strain 
and denatures surfactant. Finally, epithelial and 
endothelial injury results in translocation of 
proinflammatory mediators and bacterial prod-
ucts, leading to worsening systemic inflamma-
tion (biotrauma).
Clinical practice guidelines endorsed by mul-
tiple professional societies32 recommend invasive 
mechanical ventilation after a lowering of the 
tidal volume and airway pressure. Tidal volumes 
are reduced from 6 ml per kilogram of predicted 
body weight to a minimum of 4 ml per kilogram 
Intraalveolar
space
Basement
membrane
Surfactant
layer
Interstitial
flooding
Edema
fluid
Inflammatory
M1-like macrophage
ENaC
Na+/K+
ATPase
Interstitium
Endothelial
cell
Platelets
Red cell
Capillary
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Monocyte
Fibroblast
PRR
PAMP (e.g., LPS)
DAMP (e.g., HMGB1, mtDNA)
CD86
NETs
LTB4
ROS
Elastase or MPO
MMPs
Histones
T cell
TNF
IL-1β
IL-6
IL-8
CCL2
CCL7
etc. 
NF-κB
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bronchial epithelium
Bronchial
epithelium Bacteria, virus, fungi,
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Inactivated surfactant
Neutrophil-mediated
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Damage to basement
membrane
Hyaline membrane
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denuded basement membrane
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due to an imbalance between
procoagulants and anticoagulants
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aggregation and microthrombi formation
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if plateau airway pressures exceed 30 cm of wa-
ter. In the landmark ARDS Network trial,33 this 
approach, as compared with an approach involv-
ing a higher tidal volume, which had been used 
for decades, resulted in an absolute reduction of 
9 percentage points in mortality. The respiratory 
Figure 3. The Proliferative and Fibrotic Phases of ARDS.
The proliferative phase (Panel A) aims to restore tissue homeostasis and is characterized by the transient expansion of resident fibro­
blasts and the formation of a provisional matrix, as well as proliferation of airway progenitor cells and type II alveolar epithelial cells 
 (AECII), with differentiation into type I alveolar epithelial cells (AECI).28 During the fibrotic phase of ARDS (Panel B), which is strongly 
associated with the need for mechanical ventilation, extensive basement membrane damage and inadequate or delayed reepithelializa­
tion lead to the development of interstitial and intraalveolar fibrosis. AQP5 denotes aquaporin 5, CFTR cystic fibrosis transmembrane 
conductance regulator, GM­CSF granulocyte–macrophage colony­stimulating factor, HGF hepatocyte growth factor, IGF­I insulin­like 
growth factor I, IRF4 interferon regulatory factor 4, KGF keratinocyte growth factor, MR mannose receptor, PDGF platelet­derived growth 
factor, and TGF­β transforming growth factor β.
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rate set on the ventilator may be increased to main-
tain acceptable minute ventilation (the volume of 
gas exhaled per minute) and carbon dioxide re-
moval. However, recent preclinical and obser-
vational studies of mechanical power and energy 
transfer to the lung (proportional to lung elas-
tance, tidal volume, pulmonary resistance, and 
respiratory rate) support prospective examina-
tion of a strategy using a lower respiratory rate.34
A PEEP of at least 5 cm of water is recom-
mended, and a patient-level meta-analysis of three 
randomized trials suggests that mortality is in-
creased when the PEEP is kept relatively low, as 
compared with a strategy involving a higher 
PEEP (a mean initial PEEP of approximately 16 cm 
of water), in patients with moderate-to-severe 
ARDS.32 The optimal method for PEEP adjust-
ment is unclear.35 End-expiratory pleural pres-
sure is often positive during ARDS (especially in 
patients with high abdominal pressures or obe-
sity) and may be higher than traditionally ap-
plied levels of PEEP. This results in negative 
transpulmonary pressures at end-expiration, lead-
ing to atelectrauma. Measuring esophageal pres-
sure with a manometer to estimate pleural pres-
sure allows for adjustment of PEEP to achieve a 
positive end-expiratory transpulmonary pressure 
gradient, an approach that is increasingly used 
in clinical care. A small proof-of-concept study 
hinted at a reduction in mortality with the use 
of this strategy,36 and clinical trials are under 
way (ClinicalTrials.gov numbers, NCT01681225 
and NCT02416037). Adjusting PEEP or tidal vol-
ume to minimize driving pressure (the differ-
ence between plateau airway pressure and PEEP) 
is also rational, since with this approach, the 
tidal volume is adjusted in proportion to the 
patient’s respiratory system compliance (to avoid 
overdistention). Adjusting the PEEP to minimize 
driving pressure may align the PEEP with the 
best respiratory system compliance, thus balanc-
ing the opening of the lung (and preventing 
atelectrauma) against overdistention (limiting 
volutrauma).37
In cases of moderate-to-severe ARDS (ratio of 
the partial pressure of arterial oxygen [Pao2] to the 
fraction of inspired oxygen [Fio2], <120 mm Hg), 
ventilation while the patient is in the prone posi-
tion is associated with reduced mortality and is 
currently recommended.30,32,38 A benefit is likely 
to accrue from reducing the risk of ventilator-
associated lung injury through the combined 
effects of more uniform distribution of ventila-
tion and less compression of the left lower lobe 
(by the heart).39 As compared with deep sedation 
alone, neuromuscular blockade has been shown 
to improve outcomes in patients with moderate-
to-severe ARDS (Pao2:Fio2, <150 mm Hg), possi-
bly because neuromuscular blockage ensures 
patient–ventilator synchrony, which in turn re-
duces the risk of ventilator-associated lung in-
jury.40 However, deep sedation may be associated 
with deleterious effects on its own. Consequent-
ly, another large, randomized clinical trial in-
volving patients with moderate-to-severe ARDS 
is comparing neuromuscular blockade and deep 
sedation with no routine neuromuscular block-
ade and less sedation (NCT02509078).41
High-frequency oscillation offers no advan-
tage over conventional ventilation strategies and 
may be harmful, though a patient-level meta-
analysis has suggested a benefit when the 
Pao2:Fio2 ratio is less than 60 mm Hg.
42-44 Airway 
pressure release ventilation (i.e., applied contin-
uous positive airway pressure that at a set inter-
val releases the applied pressure) may improve 
oxygenation and tolerance of mechanical venti-
lation but has not been proved to reduce mortal-
ity. Both these ventilation strategies may improve 
oxygenation by increasing the mean airway pres-
sure, which may adversely affect hemodynamics. 
Extracorporeal membrane oxygenation (ECMO) 
is reserved for patients with very severe ARDS 
(Pao2:Fio2, <60 mm Hg) after adequate lung-
protective practices and correction of volume 
overload have failed to improve oxygenation. 
One randomized trial suggested a benefit with 
referral to an ECMO center, although it is un-
clear whether the benefit was simply from better 
specialized care, since not all referred patients 
were treated with ECMO.45 A multicenter, ran-
domized trial to further test the benefits of 
ECMO is ongoing (NCT01470703).
Noninvasive ventilation may increase the risk 
of death when attempted in patients with severe 
hypoxemia, perhaps by facilitating high tidal 
volumes from the combined effects of the high 
respiratory drive and respiratory support (result-
ing in ventilation-induced lung injury).46,47 Oxygen 
administration through high-flow nasal cannu-
lae and noninvasive ventilation provided with a 
helmet may be effective alternatives to intuba-
tion and mechanical ventilation in patients with 
less severe ARDS. Both approaches have the 
potential to reduce respiratory drive and the risk 
of ventilation-induced lung injury.47
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A conservative f luid-management strategy 
shortened the duration of assisted ventilation in 
a large randomized trial,48 and the benefit ap-
pears to occur largely from avoidance of fluid 
administration after reversal of shock.49 Small 
randomized trials of diuretics and albumin after 
shock reversal showed improved oxygenation and 
a trend toward a shorter duration of mechanical 
ventilation,50,51 but a larger trial did not suggest 
a reduction in mortality with the use of albumin 
in a general ICU population.52 Albumin may be 
harmful in patients with traumatic brain injury.53 
For nutritional support, trophic and early full-
calorie enteral nutrition are equivalent with re-
gard to mortality,54 and aggressive early caloric 
supplementation with parenteral nutrition may 
be harmful.55
Pharmacologic Therapy
Unfortunately, no pharmacologic therapy for ARDS 
has been shown to reduce either short-term or 
long-term mortality. Inhaled nitric oxide tran-
siently improves oxygenation and may improve 
long-term lung function among patients who 
survive, but it does not reduce mortality and is 
associated with acute kidney injury.56 Glucocorti-
coids may improve oxygenation and airway pres-
sures and, in patients with pneumonia, may 
hasten radiographic improvement, but these 
agents are not associated with a consistent sur-
vival benefit and are harmful if started 14 days 
or more after ARDS has been diagnosed.57 Sur-
factant replacement, neutrophil elastase inhibi-
tion, and anticoagulation have failed in clinical 
trials, as have nonsteroidal antiinflammatory 
agents (ketoconazole and lysofylline), statins, 
albuterol, and antioxidants (procysteine [l-2-oxo-
thiazolidine-4-carboxylic acid]), though many of 
these trials had relatively small samples, and in 
some cases, the doses tested did not modulate 
the intended biologic targets.58 A trial of nebu-
lized heparin is under way after promising early-
phase testing (Australian New Zealand Clinical 
Trials Registry number, ACTRN12612000418875). 
A novel therapeutic approach in early clinical de-
velopment involves intravenous delivery of mesen-
chymal stem cells, which interact with injured 
tissue through the release of multiple soluble 
bioactive factors.59
Prevention
With regard to prevention, observational studies 
indicate that a bundle of good ICU practices, 
such as lower tidal volumes for all mechanically 
ventilated patients, early volume resuscitation and 
antibiotics for sepsis, male-donor plasma and 
restrictive use of blood products (to reduce the 
risk of transfusion-associated lung injury and 
volume overload), and intensivist involvement 
prevent the development of nosocomial ARDS.17 
Patients at risk for ARDS can be identified pro-
spectively, allowing for trials of prevention and 
early treatment. The National Heart, Lung, and 
Blood Institute has funded a clinical trials net-
work for this purpose. Thus far, glucocorticoids, 
aspirin, and beta-agonists have failed in preven-
tion trials, although inhaled beta-agonists pre-
vent high-altitude pulmonary edema and, in one 
small pilot trial, the combination of beta-ago-
nists and glucocorticoids prevented the develop-
ment of ARDS (but did not reduce mortality).17
The Se a rch for Tr e atmen t-
R esponsi v e Subt y pes
Patients at the more severe end of the ARDS 
spectrum have, on average, greater lung weights 
and higher rates of diffuse alveolar damage and 
pneumonia on biopsy or postmortem examina-
tion, and such patients are more likely to die 
from refractory hypoxemia than from multior-
gan failure, which is the most common cause of 
death in all patients with ARDS.60 As noted 
above, the subset of patients with severe ARDS 
appears to derive a survival benefit from treat-
ments aimed at preventing ventilator-associated 
lung injury, including ventilation in the prone 
position and higher PEEP, two interventions that 
failed in unselected ARDS populations. How-
ever, lung histologic features are quite variable 
in all the Berlin definition subgroups,10 including 
severe ARDS, and it is likely that distinct molecu-
lar mechanisms are involved.61,62 A more precise 
medical approach will probably be necessary to 
identify pharmacotherapies for ARDS. For exam-
ple, by merging clinical and biologic variables 
with genetic features, subphenotypes within asth-
ma have been consistently identified, linked to 
specific molecular pathways, and shown to be 
responsive to different treatments.63 This trans-
formative approach to asthma is now unfolding 
for ARDS.
The most promising of these approaches in-
volves latent class analysis of baseline clinical, 
laboratory, and protein biomarker levels, which 
has consistently identified a subpopulation of 
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patients with ARDS enrolled in clinical trials.61,62 
These patients, representing approximately one 
third of all patients with ARDS, have a “hyper-
inflammatory” subphenotype, with elevated plas-
ma levels of interleukin-6, interleukin-8, and 
tumor necrosis factor α and reduced levels of 
bicarbonate and protein C. Sepsis and vasopres-
sor use have been more common in this sub-
population than in other patients with ARDS, 
and mortality has been nearly twice as high, 
with randomized assignment to higher PEEP or 
conservative fluid management associated with 
a reduction in mortality.61,62 Classification of the 
severity of ARDS and use of traditional clinical 
variables or severity-of-illness scores, such as the 
Acute Physiology, Age, and Chronic Health Eval-
uation (APACHE) III score, could not identify 
patients with this treatment-responsive subtype, 
but a relatively simple assessment of three to five 
biomarkers could. The biologic processes driv-
ing class assignment are unclear, and these 
promising findings require prospective valida-
tion. Additional approaches to the identification 
of treatment targets and responsive subtypes are 
described in the Supplementary Appendix.
Conclusions
We now recognize that ARDS, like asthma, is a 
syndrome characterized by substantial heteroge-
neity.63 A much better understanding of the bio-
logic and genetic underpinnings of the subphe-
notypes of ARDS should lead the way to more 
targeted therapies. Until then, ICU practices that 
prevent ARDS, early and effective treatment of 
the insults leading to ARDS, and lung-protective 
ventilation and sensible fluid management re-
main the essential elements for good outcomes.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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